756 related articles for article (PubMed ID: 35046084)
1. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
Iaffaldano P; Lucisano G; Manni A; Paolicelli D; Patti F; Capobianco M; Brescia Morra V; Sola P; Pesci I; Lus G; De Luca G; Lugaresi A; Cavalla P; Montepietra S; Maniscalco GT; Granella F; Ragonese P; Vianello M; Brambilla L; Totaro R; Toscano S; Malucchi S; Petracca M; Moiola L; Ferraro D; Lepore V; Mosconi P; Ponzio M; Tedeschi G; Comi G; Battaglia MA; Filippi M; Amato MP; Trojano M;
Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35046084
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
Reder AT; Centonze D; Naylor ML; Nagpal A; Rajbhandari R; Altincatal A; Kim M; Berdofe A; Radhakrishnan M; Jung E; Sandrock AW; Smirnakis K; Popescu C; de Moor C
CNS Drugs; 2021 Mar; 35(3):317-330. PubMed ID: 33743151
[TBL] [Abstract][Full Text] [Related]
3. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
Safavi F; Nourbakhsh B; Azimi AR
Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
[TBL] [Abstract][Full Text] [Related]
4. Antibodies against SARS-CoV-2 S and N proteins in relapsing-remitting multiple sclerosis patients treated with disease-modifying therapies.
Kulikowska J; Czarnowska A; Gudowska-Sawczuk M; Kulczyńska-Przybik A; Bazylewicz M; Collins F; Chorąży M; Mroczko B; Kochanowicz J; Kapica-Topczewska K; Kułakowska A
Neurol Neurochir Pol; 2023; 57(1):121-130. PubMed ID: 36421067
[TBL] [Abstract][Full Text] [Related]
5. Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients.
Gil-Bernal R; González-Caballero JL; Espinosa-Rosso R; Gómez-Gómez C
Sci Rep; 2021 Jun; 11(1):12533. PubMed ID: 34131191
[TBL] [Abstract][Full Text] [Related]
6. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
[TBL] [Abstract][Full Text] [Related]
7. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
Brown JWL; Coles A; Horakova D; Havrdova E; Izquierdo G; Prat A; Girard M; Duquette P; Trojano M; Lugaresi A; Bergamaschi R; Grammond P; Alroughani R; Hupperts R; McCombe P; Van Pesch V; Sola P; Ferraro D; Grand'Maison F; Terzi M; Lechner-Scott J; Flechter S; Slee M; Shaygannejad V; Pucci E; Granella F; Jokubaitis V; Willis M; Rice C; Scolding N; Wilkins A; Pearson OR; Ziemssen T; Hutchinson M; Harding K; Jones J; McGuigan C; Butzkueven H; Kalincik T; Robertson N;
JAMA; 2019 Jan; 321(2):175-187. PubMed ID: 30644981
[TBL] [Abstract][Full Text] [Related]
8. Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients.
Mallucci G; Zito A; Baldanti F; Gastaldi M; Fabbro BD; Franciotta D; Bergamaschi R
Mult Scler Relat Disord; 2021 Apr; 49():102754. PubMed ID: 33609958
[TBL] [Abstract][Full Text] [Related]
9. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.
Sormani MP; De Rossi N; Schiavetti I; Carmisciano L; Cordioli C; Moiola L; Radaelli M; Immovilli P; Capobianco M; Trojano M; Zaratin P; Tedeschi G; Comi G; Battaglia MA; Patti F; Salvetti M;
Ann Neurol; 2021 Apr; 89(4):780-789. PubMed ID: 33480077
[TBL] [Abstract][Full Text] [Related]
10. Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.
Simpson-Yap S; De Brouwer E; Kalincik T; Rijke N; Hillert JA; Walton C; Edan G; Moreau Y; Spelman T; Geys L; Parciak T; Gautrais C; Lazovski N; Pirmani A; Ardeshirdavanai A; Forsberg L; Glaser A; McBurney R; Schmidt H; Bergmann AB; Braune S; Stahmann A; Middleton R; Salter A; Fox RJ; van der Walt A; Butzkueven H; Alroughani R; Ozakbas S; Rojas JI; van der Mei I; Nag N; Ivanov R; Sciascia do Olival G; Dias AE; Magyari M; Brum D; Mendes MF; Alonso RN; Nicholas RS; Bauer J; Chertcoff AS; Zabalza A; Arrambide G; Fidao A; Comi G; Peeters L
Neurology; 2021 Nov; 97(19):e1870-e1885. PubMed ID: 34610987
[TBL] [Abstract][Full Text] [Related]
11. Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies.
Smith TE; Madhavan M; Gratch D; Patel A; Saha V; Sammarco C; Rimler Z; Zuniga G; Gragui D; Charvet L; Cutter G; Krupp L; Kister I; Ryerson LZ
Mult Scler Relat Disord; 2022 Apr; 60():103735. PubMed ID: 35398713
[TBL] [Abstract][Full Text] [Related]
12. Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data.
Chen J; Taylor BV; Blizzard L; Simpson S; Palmer AJ; van der Mei IAF
J Neurol Neurosurg Psychiatry; 2018 Nov; 89(11):1200-1207. PubMed ID: 29921609
[TBL] [Abstract][Full Text] [Related]
13. Disease-modifying therapies and cost-of-illness progression among people newly diagnosed with multiple sclerosis: a national register-based cohort study covering treatment initiation with interferons, glatiramer acetate or natalizumab.
Karampampa K; Gyllensten H; Friberg E; Murley C; Kavaliunas A; Hillert J; Olsson T; Alexanderson K
BMJ Open; 2023 May; 13(5):e067516. PubMed ID: 37192793
[TBL] [Abstract][Full Text] [Related]
14. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.
Czarnowska A; Brola W; Zajkowska O; Rusek S; Adamczyk-Sowa M; Kubicka-Bączyk K; Kalinowska-Łyszczarz A; Kania K; Słowik A; Wnuk M; Marona M; Podlecka-Piętowska A; Nojszewska M; Zakrzewska-Pniewska B; Jasińska E; Gołuch K; Lech B; Noga M; Perenc A; Popiel M; Lasek-Bal A; Puz P; Maciejowska K; Kucharska-Lipowska M; Lipowski M; Kapica-Topczewska K; Chorąży M; Tarasiuk J; Kochanowicz J; Kulikowska J; Wawrzyniak S; Niezgodzińska-Maciejek A; Pokryszko-Dragan A; Gruszka E; Budrewicz S; Białek M; Kurkowska-Jastrzębska I; Kurowska K; Stępień A; Włodek A; Ptasznik V; Pawełczyk M; Sobolewski P; Lejmel H; Strzalińska K; Maciejowski M; Tutaj A; Zwiernik J; Litwin A; Lewańczyk B; Paprocka I; Zwiernik B; Pawlos A; Borysowicz A; Narożnik A; Michałowska A; Nosek K; Fudala M; Milewska-Jędrzejczak M; Kułakowska A; Bartosik-Psujek H
Neurol Neurochir Pol; 2021; 55(2):212-222. PubMed ID: 33856686
[TBL] [Abstract][Full Text] [Related]
15. A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.
Torres P; Sancho-Saldaña A; Gil Sánchez A; Peralta S; Solana MJ; Bakkioui S; González-Mingot C; Quibus L; Ruiz-Fernández E; San Pedro-Murillo E; Brieva L
J Neurol; 2023 May; 270(5):2380-2391. PubMed ID: 36933032
[TBL] [Abstract][Full Text] [Related]
16. The impact of hybrid immunity on immune responses after SARS-CoV-2 vaccination in persons with multiple sclerosis treated with disease-modifying therapies.
Rabenstein M; Thomas OG; Carlin G; Khademi M; Högelin KA; Malmeström C; Axelsson M; Brandt AF; Gafvelin G; Grönlund H; Kockum I; Piehl F; Lycke J; Olsson T; Hessa T
Eur J Neurol; 2023 Dec; 30(12):3789-3798. PubMed ID: 37522464
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial.
Diouf I; Malpas CB; Sharmin S; Roos I; Horakova D; Kubala Havrdova E; Patti F; Shaygannejad V; Ozakbas S; Eichau S; Onofrj M; Lugaresi A; Alroughani R; Prat A; Duquette P; Terzi M; Boz C; Grand'Maison F; Sola P; Ferraro D; Grammond P; Yamout B; Altintas A; Gerlach O; Lechner-Scott J; Bergamaschi R; Karabudak R; Iuliano G; McGuigan C; Cartechini E; Hughes S; Sa MJ; Solaro C; Kappos L; Hodgkinson S; Slee M; Granella F; de Gans K; McCombe PA; Ampapa R; van der Walt A; Butzkueven H; Sánchez-Menoyo JL; Vucic S; Laureys G; Sidhom Y; Gouider R; Castillo-Trivino T; Gray O; Aguera-Morales E; Al-Asmi A; Shaw C; Al-Harbi TM; Csepany T; Sempere AP; Treviño Frenk I; Stuart EA; Kalincik T
J Neurol Neurosurg Psychiatry; 2023 Dec; 94(12):1004-1011. PubMed ID: 37414534
[TBL] [Abstract][Full Text] [Related]
18. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
Johnson KM; Zhou H; Lin F; Ko JJ; Herrera V
J Manag Care Spec Pharm; 2017 Aug; 23(8):844-852. PubMed ID: 28737986
[TBL] [Abstract][Full Text] [Related]
19. Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis.
Harding K; Williams O; Willis M; Hrastelj J; Rimmer A; Joseph F; Tomassini V; Wardle M; Pickersgill T; Robertson N; Tallantyre E
JAMA Neurol; 2019 May; 76(5):536-541. PubMed ID: 30776055
[TBL] [Abstract][Full Text] [Related]
20. Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β.
Simpson-Yap S; Pirmani A; De Brouwer E; Peeters LM; Geys L; Parciak T; Helme A; Hillert J; Moreau Y; Edan G; Spelman T; Sharmin S; McBurney R; Schmidt H; Bergmann A; Braune S; Stahmann A; Middleton R; Salter A; Bebo B; van der Walt A; Butzkueven H; Ozakbas S; Karabudak R; Boz C; Alroughani R; Rojas JI; van der Mei I; Sciascia do Olival G; Magyari M; Alonso R; Nicholas R; Chertcoff A; Zabalza A; Arrambide G; Nag N; Descamps A; Costers L; Dobson R; Miller A; Rodrigues P; Prčkovska V; Comi G; Kalincik T
Mult Scler Relat Disord; 2022 Oct; 66():104072. PubMed ID: 35917745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]